Tango Therapeutics, Inc. (TNGX)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Biotech / Pharmasrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-13. ClinicalTrials.gov
Dilution Risk
LOW DILUTION RISKDilution score: 21/100 (LOW), 76.6 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 63.94% of float, squeeze risk: HIGH
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Tango Therapeutics to Present Updated Vopimetostat + RAS(ON) Combination Data at European Society For Medical Oncology (ESMO) Congress 2026
- Why Is Tango Therapeutics (TNGX) Down 6.2% Since Last Earnings Report?
- Tango Therapeutics (TNGX) At 3.7x P B As Pullback Tests Whether It Looks Pricey
- Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Tango Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference
- Tango Therapeutics Announces Executive Chair Transition
- How Much Upside is Left in Tango Therapeutics (TNGX)? Wall Street Analysts Think 49.48%
- Tango Therapeutics (TNGX) to Benefit From Vopimetostat + KRAS Inhibitors Combined Revenues
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Recent Publications
- It takes two to tango: the intersection of deubiquitinases and m(6)A modification in cancer. — Mol Cancer 2026 Oct 14 PMID 42881390
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Tango Therapeutics, Inc..
Full TNGX Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.